TFF1
The CCAAT element binding protein beta (C/EBPb) is a member of the transcriptional factor family consisting of six functionally and structurally related basic leucine zipper DNA-binding proteins. C/EBP family members include C/EBPa, C/EBPb, C/EBPg, C/EBPd, C/EBPe and C/EBPx; all of which bind to the same CCAAT palindromic DNA sequence through homo-or heterdimerization with other family members (Vinson et al., 1989) . The genes regulated by the C/EBP proteins are diverse and involved in a variety of different cell processes including metabolism, hematopoiesis, adipogenesis, immune system and morphogenesis. C/EBP proteins are regulated in response to a variety of stimuli including hormonal, cytokine and growth factor-signaling pathways. The C/EBPb gene is located on the long arm of chromosome 20 (20q) , where DNA copy number amplification has been observed in a wide variety of cancers including gastric, prostate, ovarian, colorectal, pancreatic and bladder cancers. Indeed, the most frequent amplified chromosomal region in gastric cancers (GC) was observed at 20q (El-Rifai et al., 2001) .
We recently identified C/EBPb binding sites in the promoter of TFF1 and demonstrated in vitro its binding and downregulation of its activity (Sankpal et al., 2005) . Gastrointestinal mucosal protection by the TFF protein family has attracted attention, especially in the stomach with the observance that Tff1 knockout mice display aberrant gastric mucosa characterized by the eventual development of gastric dysplasia and cancer (Lefebvre et al., 1996) . Moreover, this important molecule in gastric mucosal homeostasis was observed to have significantly low expression in the majority of GC; however, the cause of its dysregulation remains to be delineated. Although there are likely to be numerous mechanisms by which TFF1 gene transcription is inhibited, recent work suggests one pathway may be inhibition of IL-6 signaling via MAPK activation leading to inhibition of TFF1 (Tebbutt et al., 2002; Judd et al., 2004) .
In the present work, the expression of C/EBP and trefoil factor family members in gastric tumors is compared to the expression in non-neoplastic gastric tissue samples. We report the novel finding of C/EBPb overexpression in the majority of gastric tumors and its association with loss of TFF1.
The expression levels of members of the transcription factor C/EBP family were specifically studied in an analysis of 27 gastric tumors and 12 normal gastric tissue samples employing the Affymetrix U133 RNA oligonucleotide microarray chip. C/EBPb was found to be one of the most significant as well as consistently overexpressed genes in the gastric tumors relative to normal gastric tissue samples. Statistical analysis revealed that C/EBPb mRNA levels were increased in 25 gastric tumors at least fivefold or higher compared to the 12 normal gastric tissue samples. (Figure 1a and b) . The substantial increase in C/EBPb gene expression was observed in both primary and xenografted gastric tumors. Five of six primary GCs demonstrated increased expression of C/EBPb. In total, 20 of 21 xenografts exhibited significantly higher expression of C/EBPb. The overexpression of C/EBPb was in the order of fivefold (Po0.01) for primary cancer and 3.5-fold for xenograft samples when compared to 12 normal gastric tissue samples. No specific association of increased expression of C/EBPb was observed with any particular clinicopathologic feature of the gastric tumors.
C/EBPa (NM_004364.1), C/EBPg (NM_001806.1), C/EBPx (NM_004083.1) and C/EBPe (NM_001805.1) did not exhibit a change in expression level in gastric tumors relative to normal gastric tissues. Noteworthy, the expression level of C/EBPd (NM_005195.1) was high in primary gastric tumors but not in xenografted gastric tumors (Figure 1a ). TFF1 and TFF2 RNA levels were abundant in normal gastric tissues as expected (see Figure 1c and d). On the other hand, little expression of TFF1 was noted in normal esophageal tissue. Intestinal protein, TFF3, was hardly detectable in normal as well as primary and xenografted gastric tumor tissues. The overall expression level of TFF1 in normal gastric tissue was 12-fold higher than five primary gastric tumors (excluding G334) and more than sixfold higher Tumor   Gastric   G334  G328  G296  G280  G234  G208  X156  X155  X152  X143  X116  X102  X79  X76  X75  X71  X65  X58  X57  X56  X55  X51  X49  X46  X43  X20  X11  N334-ESO   N334  N285  N257  N445- , and 95% confidence interval (error bars) for each group of samples. Surgically resected tissue specimens of gastric adenocarcinomas and in some cases adjacent normal gastric mucosa were collected from patients at the University of Virginia Health System, Indiana University, Johns Hopkins University, and from Siena, Italy, according to protocols approved by internal review boards and described (Beckler et al., 2003) . RNA extraction, cRNA synthesis and GeneChip hybridizations were performed as described previously (Welsh et al., 2001) . Raw data from the GeneChips were processed using MAS5.0 (Affymetrix, Santa Clara, CA, USA), scaled to an average difference value of 200, and collated in MS-Excel for further analysis. Agglomerative clustering was performed using Cluster, and the results of clustering visualized in Treeview.
compared to 20 xenografted gastric tumors. A similar pattern of low expression in gastric tumors compared to normal gastric tissue was observed for TFF2 (see Figure  1a and d). Thus, the expression of both TFF1 and TFF2 is decreased in the majority of gastric tumors. Primary tumor, G334, was the only GC that expressed a relatively high level of TFF1 when compared to other gastric tumor samples. Interestingly, this tumor also exhibited a relatively low level of C/EBPb transcript compared to other gastric tumors.
To further demonstrate the overexpression we used real-time PCR to quantitate transcript levels in the GC samples. Increased C/EBPb transcript levels in GCs compared to normal gastric tissue levels were confirmed on 18 of those tumors studied by microarray analysis. An additional 41 gastric tumors and 18 normal gastric tissue RNA samples were studied by quantitative RT-PCR analysis. A Box-Whisker plot of the C/EBPb transcription levels observed in the primary GCs, xenografted gastric tumors, and normal gastric tissue samples is presented in Figure 2a . All 18 normal gastric tissue samples had lower transcript levels of C/EBPb with a mean value of 0.38 (s.d., 70.49) arbitrary units. On the other hand, the relative abundance of C/EBPb transcript levels for 59 gastric tumors was increased with a mean value of 1.8 (s.d., 70.79) for the 24 primary cancers and 2.2 (s.d., 70.85) for the xenografted tumors. The increase in C/EBPb transcript level compared to the normal gastric tissue samples was 4.5 and 5.5-fold for primary and xenografted tumors, respectively. The threshold cycles for the b-amyloid precursor protein that was used for normalization demonstrated minimal variation in all the tumor and normal samples studied.
Further, comparison of transcript abundance between gastric tumor samples and their corresponding adjacent normal gastric tissue from the same patient was able to be performed on 18 paired mRNA samples, which allowed investigation of the tissue specific expression of C/EBPb. This analysis revealed that 15 of 18 (83%) primary tumors overexpressed C/EBPb when compared to their corresponding normal tissue sample (Figure 2b ). Only three of these gastric tumors (G236, G257 and G297) exhibited lower levels of C/EBPb transcript compared to their corresponding adjacent normal gastric tissue. Interestingly, G236 and G257 are tumors from the distal region of the stomach having a mixed type (intestinal and diffuse) histopathology and advance Tumor-Node-Metastasis stage (IIIA and IV).
Quantitative RT-PCR analysis of TFF1 in these 59 gastric carcinoma tissue samples demonstrated consistently low and often undetectable levels of transcript when compared to normal gastric tissues (see Figure 3a) . In addition to the 23 cases that previously demonstrated low transcript levels of TFF1 (Beckler et al., 2003) A total of 5 ml of each amplified RT-PCR product was electrophoretically run through 1.2% agarose gels and stained with ethidium bromide to visually confirm the quantitative real-time RT-PCR data. The b-amyloid RT-PCR products were also run as controls. N: non-neoplastic gastric mucosa sample; G: primary GC sample. The staining demonstrates the clear presence of significantly higher C/EBPb transcript levels in most of the GC samples compared with their corresponding adjacent non-neoplastic gastric mucosa samples. RNA purification, cDNA synthesis and real-time RT-PCR analysis were performed as previously described (Beckler et al., 2003) .
transcript levels less than 50% of those observed in the normal tissue samples (Figure 3a) . Three gastric tumor samples (G234/G247/G248) displayed a relatively high TFF1 transcript level compared with the other tumor samples, which was also observed in the oligonucleotide microarray findings. Although these three gastric tumors exhibited TFF1 expression above the mean of the other tumor samples, the transcript levels were still significantly lower than the mean of the 18 normal tissue samples. Altered expression of TFF1 occurred irrespective of the gastric carcinoma subtype. In comparison of the 18 patients' gastric tumor and their corresponding adjacent non-neoplastic gastric mucosa tissue, TFF1 transcript levels were consistently lower in all 18 tumors. The paired normal gastric tissue samples contained a relatively high abundance of TFF1 transcript (Figure 3b ), whereas the primary gastric tumor samples exhibited a significant reduction of TFF1 transcript levels when compared to corresponding non-neoplastic gastric tissue samples. These 18 normal and tumor samples exhibited a mean relative transcript level of 5.45 (s.d., 70.59) and 0.20 (s.d. 70.78) arbitrary units, respectively. Taken together, TFF1 transcript level was at least 25-fold higher in the normal gastric tissue compared to the corresponding gastric tumor. These 18 tumors from the tumor-normal pair were also analysed using linear regression models. The most robust quantitative RT-PCR data was used for regression analysis to evaluate the relation between C/EBPb and TFF1 (Figure 3d ). The P-values obtained for this analysis of tumors, P ¼ 0.005, was significant. The R 2 values of 68% observed for C/EBPb against TFF1 show a strong inverse relationship. Additionally, the corresponding normal tissues also demonstrated an inverse relationship when fitted in regression models with R 2 ¼ 60% and Po0.03 (data not shown). Overall, the 59 GC cases studied exhibited significant downregulation of TFF1 (5.45-0.205), of which 56 GC cases also demonstrated upregulation specifically for C/EBPb (0.38-2.0) suggesting a reciprocal relationship.
Tissue samples of gastric tumors and adjacent normal gastric mucosa that were available for sectioning and staining with an antibody to C/EBPb were studied by A total of 5 ml of each amplified RT-PCR product were electrophoretically run through 1.2% agarose gels and stained with ethidium bromide to visually confirm the quantitative real-time RT-PCR data. The b-amyloid RT-PCR products were also run as controls. N ¼ non-neoplastic gastric mucosa sample; G ¼ primary GC sample. The staining demonstrates the clear presence of significantly lower TFF1 transcript levels in each of the GC samples compared with its corresponding adjacent non-neoplastic gastric mucosa sample. RNA purification, cDNA synthesis and real time RT-PCR analysis was performed as previously described (Beckler et al., 2003) . immunohistochemistry (IHC) to localize and semiquantitate its expression. A predominantly nuclear pattern of C/EBPb protein expression was observed. All normal gastric mucosa had nuclear staining scores of 1 (o20% nuclear staining). Overall, an increased expression of nuclear C/EBPb protein was observed in gastric tumors with a relatively high intensity pattern of nuclear C/EBPb staining observed in 10 of 13 (76%) gastric tumors analysed. The gastric tumors G173, G175 and G286 had IHC scores of 5 (>80% nuclear staining), G235, G236 with scores of 4 (nuclear staining 60-80%), G260, G270 with scores of 3 (nuclear staining 40-60%) and G207, G226, G329 with scores of 2 (20-40% nuclear staining). The 10 gastric tumors having IHC scores of more than 2 also had high transcript abundance of C/EBPb and all 13 of these gastric tumors had low transcripts of TFF1 by quantitative RT-PCR analysis. Immunohistochemical staining of three representative primary gastric tumors (G235, G286 and G270) with their corresponding adjacent normal gastric mucosa is presented in Figure 4 . Furthermore, oligonucleotide microarray and quantitative RT-PCR findings of RNA analyses on these tissue samples demonstrated increased transcript abundance of C/EBPb in the gastric tumor samples when compared to each corresponding non-neoplastic gastric tissue (Figure 4b ). These tissue samples had already shown decreased abundance of TFF1 in our previous study at the protein and transcript levels (Beckler et al., 2003) . Thus, increased expression of nuclear C/EBPb protein correlated with decreased TFF1 levels at the protein as well as transcript levels. Although overexpression of C/EBPb has been reported in several cancers including breast (Kagan et al., 2003) , ovary (Sundfeldt et al., 1999) and colon (Rask et al., 2000) , this is a novel finding for GC.
Evidence is mounting in implicating C/EBPb as an oncogene. The most recent report demonstrated the role of C/EBPb in contributing to the prognosis and survival of cultured Wilms tumor suggesting that C/EBPb is involved in the development and/or progression of Wilms tumor (Li et al., 2005) . Enforced expression of C/EBPb in MCF10A (normal immortalized) mammary epithelial cells induces a neoplastic phenotype, including focal growth, anchorage independence and increased invasiveness in vitro (Bundy and Sealy, 2003) . C/EBPb was found to be significantly increased in human colorectal tumors with a potential role as a transcriptional regulator of genes responsible for invasion of surrounding tissue (Rask et al., 2000) . Furthermore, the increased activation of C/EBPb is suggested to promote tumor invasiveness in renal cell carcinoma (Oya et al., 2003) . Moreover, increased expression of C/EBPb was observed to be associated with human ovarian epithelial tumor progression (Sundfeldt et al., 1999) . Thus, the activation of C/EBPb may be an important event in the development of epithelial tumors.
The exact mechanism of C/EBPb leading to carcinogenesis has yet to be delineated. Several potential oncogenic effects of C/EBPb have been reported. Cyclin-D1 and C/EBPb have been shown to interact physically. The activity of cyclin-D1 was shown to be mediated in part by its association with C/EBPb, resulting in expression of a novel set of growthpromoting genes (Lamb et al., 2003) . C/EBPb was found to be a transcription factor for cyclooxygenase (COX)-2 gene regulation, which has been observed to be overexpressed in precancerous gastric lesions and GC (Gorgoni et al., 2001) . C/EBPb was also found to physically interact with RUNX2 and synergistically activate the osteocalcin promoter (Gutierrez et al., 2002) to form a complex with p300 and together upregulate basal tissue-specific transcription. Finally, the Akt/PI3-kinase signaling pathway has been observed to be involved in the activation of C/EBPb (Kang et al., 2003) .
C/EBPb has multiple isoforms (p55, p45/42 doublet and p20 in humans) suggesting how a single transcription factor can exhibit contrasting influences on both differentiation and proliferation. Both C/EBPb-LAP and C/EBPb-LIP isoforms were expressed in approximately 70% of breast tumors, with LIP expressed at high levels suggesting a role in human breast tumorigenesis (Zahnow et al., 1997) . Kowenz-Leutz and Leutz (1999) reported that only the largest C/EBPb isoform is able to cooperate with Myb to activate the mim-1 gene and other myeloid-specific genes in chromatin. They demonstrated that C/EBPb-1 interacts with the SWI/SNF chromatin-remodeling complex, whereas C/EBPb-2 (LAP) does not. Interestingly, the N-terminal 21 amino acids of LAP were shown to be essential, although not sufficient, for recruitment of the SWI/SNF complex (Kowenz-Leutz and Leutz, 1999) . The retroviral oncogene Myb is shown to stimulate C/EBPb expression by acting on the promoter as well as on an enhancer of the C/EBPb gene (Kintscher et al., 2004) .
Recent studies suggest that C/EBPb may be an important regulator of TFF1 expression. C/EBPb has been implicated in transcriptional regulation of all three trefoil factor family members (Dossinger et al., 2002) . C/EBPb coexpression was demonstrated to repress TFF1 promoter activity. The TFF1 promoter contains conserved C/EBPb binding sites in the 2-kb upstream sequence. We most recently demonstrated decreased TFF1 promoter activity with C/EBPb binding within a repressor region of the TFF1 promoter (Sankpal et al., 2005) . Our current findings in this study of gastric tumors provide additional in vivo evidence that C/EBPb may be an important repressor of TFF1 in GC cells. Our finding of low expression of TFF1 and TFF2 mRNA in most gastric tumors is in agreement with earlier reports (Hasegawa et al., 2002; Beckler et al., 2003) . Striking was the finding of a significant reciprocal correlation of high C/EBPb expression and loss of TFF1 expression in the majority of gastric tumors studied. Additional studies will delineate how C/EBPb may repress TFF1 expression and if additional cofactors are involved in this process.
Overall, our novel finding of elevated C/EBPb expression in the majority of gastric tumors has important implications. The transcript of C/EBPb was increased in 84% of gastric tumors at least fivefold over normal gastric samples. IHC analysis confirmed the overexpression of C/EBPb in the nucleus at the protein level. Additionally, the reciprocal correlation of increased C/EBPb expression to the decreased TFF1 in most of the GCs studied suggests a significant interaction that deserves further investigation. The three representative GC demonstrated 60-100% nuclear staining in surface and foveolar epithelial cells, whereas the adjacent normal gastric specimens all showed less than 30% staining of cells. IHC was performed with the polyclonal anti-C/EBPb antibody. The cases from the top down are paired gastric tumor and adjacent normal specimens: G/N 235, G/N 286, G/N270. The left panels display stained normal gastric tissue specimens; the right panels display stained matched primary gastric tumor specimens. All images were captured at Â 1000 magnification. IHC was performed on formalin-fixed and paraffin-embedded histologic sections from both adjacent normal and gastric tumor tissue samples. A previously characterized commercial C/EBPb antibody (C-19) (Santa Cruz Biotechnology, CA, USA) was used for histologic staining and the methods are described (Beckler et al., 2003) . (b) Illustrates the coalition of C/EBPb expression data for these three representative cases.
